IRIS UniCatt

Armuzzi, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.449
NA - Nord America 5.611
AS - Asia 2.434
SA - Sud America 280
AF - Africa 44
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 18
Totale 15.860
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.548
DE - Germania 3.564
SE - Svezia 1.126
SG - Singapore 886
CN - Cina 866
IT - Italia 735
UA - Ucraina 516
IE - Irlanda 338
FR - Francia 332
BR - Brasile 256
GB - Regno Unito 246
ID - Indonesia 202
FI - Finlandia 173
IN - India 165
TR - Turchia 126
RU - Federazione Russa 124
PL - Polonia 60
BE - Belgio 39
CA - Canada 39
HK - Hong Kong 37
AT - Austria 35
IR - Iran 30
NL - Olanda 30
JP - Giappone 25
ES - Italia 23
AU - Australia 22
CZ - Repubblica Ceca 20
CI - Costa d'Avorio 19
CH - Svizzera 16
EU - Europa 15
PT - Portogallo 13
AR - Argentina 12
MX - Messico 12
IL - Israele 11
KR - Corea 11
HU - Ungheria 9
LT - Lituania 9
VN - Vietnam 9
IQ - Iraq 7
UZ - Uzbekistan 7
AZ - Azerbaigian 6
EG - Egitto 6
BG - Bulgaria 5
PK - Pakistan 5
RO - Romania 5
TN - Tunisia 5
AL - Albania 4
BZ - Belize 4
GR - Grecia 4
LV - Lettonia 4
MA - Marocco 4
MO - Macao, regione amministrativa speciale della Cina 4
PH - Filippine 4
RS - Serbia 4
SA - Arabia Saudita 4
DK - Danimarca 3
EC - Ecuador 3
EE - Estonia 3
JO - Giordania 3
TH - Thailandia 3
TW - Taiwan 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
BY - Bielorussia 2
CO - Colombia 2
DZ - Algeria 2
GT - Guatemala 2
JM - Giamaica 2
KG - Kirghizistan 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
MD - Moldavia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PA - Panama 2
UY - Uruguay 2
ZA - Sudafrica 2
A1 - Anonimo 1
AM - Armenia 1
AO - Angola 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BT - Bhutan 1
CG - Congo 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
HR - Croazia 1
KE - Kenya 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
PE - Perù 1
SC - Seychelles 1
Totale 15.858
Salva come PNG Salva come JPEG
Città #
Chandler 1.277
Cologne 1.211
Singapore 585
Ashburn 454
Dublin 330
Jacksonville 321
San Mateo 264
Jakarta 200
Nanjing 171
New York 169
Milan 152
Ann Arbor 150
Wilmington 141
Dearborn 134
Cattolica 123
Nürnberg 119
Beijing 115
Boston 113
Munich 108
Princeton 107
Izmir 100
Rome 89
Chicago 83
Marseille 83
Los Angeles 82
Moscow 73
Helsinki 64
Houston 63
Bremen 62
Essen 61
Nanchang 60
Woodbridge 59
Lawrence 57
Seattle 56
Redwood City 53
The Dalles 46
Fairfield 44
Hangzhou 43
Lancaster 43
Pune 40
Boardman 39
Norwalk 38
Brussels 36
Kraków 35
Mountain View 35
Hebei 34
Hong Kong 32
Nuremberg 31
Shenyang 31
Frankfurt am Main 27
Tianjin 27
Hyderabad 26
Jiaxing 26
University Park 26
Shanghai 25
São Paulo 25
Augusta 24
Düsseldorf 24
Kunming 24
Changsha 23
Guangzhou 23
Leawood 23
Toronto 20
Abidjan 19
Zhengzhou 19
Detroit 18
London 18
Washington 17
Fremont 16
Jinan 16
Lauterbourg 15
North Bergen 15
San Jose 15
Warsaw 15
Vienna 14
Andover 13
Kish 13
Redmond 13
Zurich 13
Falkenstein 12
Portsmouth 12
Council Bluffs 11
Ottawa 11
Hefei 10
Belo Horizonte 9
Brno 9
Costa Mesa 9
Edinburgh 9
Lappeenranta 9
Seoul 9
Tokyo 9
Amsterdam 8
Ardabil 8
Atlanta 8
Busto Arsizio 8
Cagliari 8
Campagna 8
Istanbul 8
Lisbon 8
Simi Valley 8
Totale 8.599
Salva come PNG Salva come JPEG
Nome #
3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management 1.310
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 325
A) Infliximab in the treatment of steroid-dependent ulcerative colitis. 265
A) Lack of endoscopic visualization of intestinal villi with the "immersion technique" in overt atrophic celiac disease 216
13C-methionine breath tests for mitochondrial liver function assessment. 213
13C-breath tests in the study of microsomal liver function 196
Sacroileitis and peripheral arthropathy associated with ulcerative colitis: effect of infliximab on both articular and intestinal symptoms 196
Growth hormone in inflammatory bowel disease 189
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study 179
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 171
134C-breath tests in the study of mitochondrial liver function 161
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 160
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 151
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 150
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 149
13C-breath tests in the study of microsomial liver function 143
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 142
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 141
13C-methionine breath tests for mitochondrial liver function assessment 138
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 136
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 133
Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations. 131
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 131
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 126
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 124
A) Advances in extracorporeal detoxification by MARS dialysis in patients with liver failure 123
Delta13CO2 excretion and expression of dyspeptic symptoms in patients evaluated for Helicobacter pylori infection by [13C] urea breath test 121
13C-breath tests in the study of mitochondrial liver function 119
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 117
ag) Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. 111
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 111
Ileal Crohn's disease: CEUS determination of activity 111
Levofloxacin based regimens for the eradication of Helicobacter pylori 110
Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study 109
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 107
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 107
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 106
Fecal calprotectin in first-degree relatives of patients with ulcerative colitis 104
-Can 13C urea breath test predict resistance to therapy in Helicobacter pylori infection? 103
Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication 103
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 103
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 101
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 98
A) Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice? 97
Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update 97
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 97
Probiotics and Helicobacter pylori eradication 93
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 93
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. 93
Helicobacter pylori treatment: a role for probiotics? 92
A novel pathogenic role for microvasculature in inflammatory bowel disease. 92
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. 91
[Helicobacter pylori and gastric carcinoma] 90
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 86
Challenges in crohn’s disease management after gastrointestinal cancer diagnosis 85
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 85
A) Study of liver function in healthy elderly subjects using the 13C-methacetin breath test 84
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. 83
Infliximab in Crohn's disease: early and long-term treatment. 83
Management of perianal fistulas in Crohn's disease: an up-to-date review 82
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 82
13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. 81
Gender affects 13C-ketoisocaproic acid breath test 80
Review article: breath testing for human liver function assessment. 80
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 79
Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease 78
Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis 77
A) Quantitative evaluation of liver function by the methionine and aminopyrine breath tests in the early stages of liver transplantation 77
Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center 77
Signs of dissociation and symptoms of post-traumatic stress disorder in inflammatory bowel disease. A case-control study 77
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 76
Mucosal healing in ulcerative colitis: surveillance or colectomy? 75
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 75
Biological therapies for inflammatory bowel disease: research drives clinics. 74
Clinical trials in ulcerative colitis: a historical perspective 74
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 74
Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence 73
Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. 72
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 72
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 70
Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement 70
Adalimumab in active ulcerative colitis: a "real-life" observational study 69
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab 69
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 69
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 68
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 68
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 67
Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease 67
Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease 66
Reply to Dr. Joob et al.'s letter 66
Inducing remission of ulcerative colitis: are clinicians better equipped than ever? 66
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease 66
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 66
Epidemiology of inflammatory bowel disease in the Republic of San Marino: The “EPIMICI – San Marino” study 65
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 65
Personalized clinical phenotyping through systems medicine and artificial intelligence 65
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 64
Frontiers in drug research and development for inflammatory bowel disease 64
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 64
Bowel contrast-enhanced ultrasound perfusion imaging in the evaluation of Crohn's disease patients undergoing anti-TNFα therapy 64
Totale 11.714
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.755
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.755
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020312 0 0 0 0 0 0 0 0 0 0 179 133
2020/20211.103 71 106 18 132 132 44 94 28 149 64 242 23
2021/20221.510 97 120 28 178 43 48 23 246 45 94 269 319
2022/20233.472 421 441 240 542 267 394 165 304 414 100 119 65
2023/20243.089 80 492 62 110 88 274 98 1.199 216 85 184 201
2024/20252.304 67 107 305 83 286 147 184 190 505 383 47 0
Totale 16.111